STUDY SEARCH RESULTS

1 study found for your search request:  3475-02C

Substudy 02C: Safety and Efficacy of Pembrolizumab in Combination with Investigational Agents or Pem...
Condition: Melanoma
Minimum Age: 18 years, Maximum Age: 120 years
Gender: All
Study ID: NCT04303169
Status: Active, not recruiting




Copyright © 2024 · Merck & Co., Inc., Rahway, NJ, USA, and its affiliates. All rights reserved. · This site is intended only for residents of the United States.
Cookie Preferences  Privacy  Terms of Use  U.S. Corporate Site